CAN-2109

To evaluate the safety and tolerability of CAN2109 in subjects with unresectable or metastatic advanced solid tumors who have failed or are intolerant to standard treatment, or who have no standard treatment. To determine the efficacy of CAN2109 in subjects with unresectable or metastatic advanced solid tumors who have failed or are intolerant to standard treatment, or who have no standard treatment. To evaluate the pharmacokinetic (PK) characteristics of CAN2109. To evaluate the pharmacodynamics (PD) of CAN2109.